One expects that a therapeutic drug will alleviate symptoms. The goal, however, is to find a cure. Note the following results from the mouse model for Fragile X;
Anxiety and locomotor activity - NNZ-2566 reduces hyperactivity
My note: it appears to be a case of alleviating symptoms
Deficit in short term memory - reversed by NNZ-2566
Abnormal social interactions - reversed by NNZ-2566
Abnormalities in CNS and peripheral morphology - reversed by NNZ-2566
My note: could this be indicative of a cure?
Could this explain why Dr Horrigan is "very excited" and why Neuren - with limited financial resources - is considering additional clinical trials in other autism spectrum disorders. It was the Army that pressed Neuren to proceed with the oral formulation for NNZ-2566 even though it had its hands full with the intravenous formulation. Expect another one of our key partners to come forward.
-
- There are more pages in this discussion • 39 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add to My Watchlist
What is My Watchlist?
 (20min delay)
|
|||||
|
Last
$14.28 |
Change
0.080(0.56%) |
Mkt cap ! $1.777B | |||
| Open | High | Low | Value | Volume |
| $14.22 | $14.55 | $14.10 | $4.611M | 320.2K |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 1 | 6352 | $14.28 |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| $14.38 | 4000 | 1 |
View Market Depth
| Last trade - 16.10pm 04/07/2025 (20 minute delay) ? |
| NEU (ASX) Chart |